Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue EJSO - European Journal of Surgical Oncology Année : 2015

Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey

1 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
2 Institut Bergonié [Bordeaux]
3 EA3738 - Ciblage thérapeutique en Oncologie
4 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
5 IGR - Institut Gustave Roussy
6 CART U965 - Carcinose Angiogenèse et Recherche Translationnelle ; Angiogenese et recherche translationnelle
7 Institut Claudius Regaud
8 CHU - Hôpital Archet 2 [Nice]
9 Hôpital de Hautepierre [Strasbourg]
10 CRLCC René Gauducheau
11 UNICANCER/CRLC - Centre Régional de Lutte contre le Cancer François Baclesse [Caen]
12 CRLC Val d'Aurelle-Paul Lamarque
13 IRCM - U1194 Inserm - UM - Institut de Recherche en Cancérologie de Montpellier
14 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
15 Hôpital Michallon
16 IPC - Institut Paoli-Calmettes
17 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
18 CHU Limoges
19 Groupe Hospitalier Diaconesses Croix Saint-Simon
20 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
21 Hôpital Robert Debré
22 UNICANCER/Lille - Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille]
23 CHU Tenon [AP-HP]
24 UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes]
25 UNICANCER/ICL - Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy]
26 Institut Curie [Paris]
27 Hôpital Claude Huriez [Lille]
28 Centre Léon Bérard [Lyon]
29 Hôpital Louis Mourier - AP-HP [Colombes]
30 Service de Chirurgie Digestive, Cancérologique, Générale, Endocrinienne et Urgences (CHU de Dijon)
31 CHU Estaing [Clermont-Ferrand]
32 TIMONE - Hôpital de la Timone [CHU - APHM]
33 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]
34 Hôpital Antoine Béclère
35 CHU Amiens-Picardie
36 CHU de Poitiers - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
37 Hôpital Charles Nicolle [Rouen]
38 HEGP - Hôpital Européen Georges Pompidou [APHP]
39 LEASP - Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps
40 HCL - Hospices Civils de Lyon
D. Elias
  • Fonction : Auteur
  • PersonId : 889253
J.M. Classe
C. Arvieux
  • Fonction : Auteur
S. Durand-Fontanier
V. Loi
  • Fonction : Auteur
C. Pomel
  • Fonction : Auteur
  • PersonId : 930198
Jean-Marc Régimbeau
Charles Sabbagh
J.J. Torrent
  • Fonction : Auteur
P. Lundberg
  • Fonction : Auteur
  • PersonId : 885290

Résumé

BACKGROUND: Over the last two decades, many surgical teams have developed programs to treat peritoneal carcinomatosis with extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Currently, there are no specific recommendations for HIPEC procedures concerning environmental contamination risk management, personal protective equipment (PPE), or occupational health supervision. METHODS: A survey of the institutional practices among all French teams currently performing HIPEC procedures was carried out via the French network for the treatment of rare peritoneal malignancies (RENAPE). RESULTS: Thirty three surgical teams responded, 14 (42.4%) which reported more than 10 years of HIPEC experience. Some practices were widespread, such as using HIPEC machine approved by the European Community (100%), individualized or centralized smoke evacuation (81.8%), "open" abdominal coverage during perfusion (75.8%), and maintaining the same surgeon throughout the procedure (69.7%). Others were more heterogeneous, including laminar flow air circulation (54.5%) and the provision of safety protocols in the event of perfusate spills (51.5%). The use of specialized personal protective equipment is ubiquitous (93.9%) but widely variable between programs. CONCLUSION: Protocols regarding cytoreductive surgery/HIPEC and the associated professional risks in France lack standardization and should be established.
Fichier non déposé

Dates et versions

hal-02334165 , version 1 (25-10-2019)

Identifiants

Citer

G. Ferron, L. Simon, F. Guyon, O. Glehen, D. Goéré, et al.. Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey. EJSO - European Journal of Surgical Oncology, 2015, 41 (10), pp.1361-1367. ⟨10.1016/j.ejso.2015.07.012⟩. ⟨hal-02334165⟩
115 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More